Global Gonorrhea Treatment Market With Emerging Key Players, Scope and Overview Forecast till 2026| Alopexx Vaccine LLC, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd

Gonorrhea treatment market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat risk associated with gonorrhea and high demand of disease specific novel therapies are the key factors that fueling the market growth.

Few of the major competitors currently working in the global gonorrhea treatment market are GlaxoSmithKline plc, MELINTA THERAPEUTICS, INC, Alopexx Vaccine LLC, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd, LUPIN, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Mylan N.V., Hikma Pharmaceuticals PLC, WOCKHARDT, Nostrum Laboratories Inc, Mayne Pharma Group Limited, Apotex Inc, Pfizer Inc, Genocea Biosciences, Inc and others

Download Sample PDF Copy of Report

Insights of the report

  1. Market Penetration: Comprehensive information on the product portfolios of the top players in the Gonorrhea Treatment market. 
  2. Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Gonorrhea Treatment market.
  3. Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
  4. Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
  5. All the Challenges and growth opportunities in the Gonorrhea Treatment market along with the market drivers and restrains.

Key Developments in the Market:

  • In October 2017, Alopexx Vaccine LLC has completed the phase I clinical trial with AV0328, a vaccine targeting poly-N-acetyl glucosamine (PNAG) for the protection against many serious and life-threatening infections such as pneumonia, meningitis, bloodstream infections, and gonorrhea. In phase I clinical trial, AV0328 demonstrated excellent well-tolerated and safe which had no overall adverse event. If trial successful it will change treatment paradigms and improve the millions of people suffering from gonorrhea.
  • In June 2017, MELINTA THERAPEUTICS, INC, reported positive result of RX-P2177, a novel pyrrolocytosine antibiotic is developing for the treatment of gonorrhea. The trial demonstrated the strong activity in vitro against contemporary clinical gonorrhea isolates, including those resistant to ceftriaxone, ciprofloxacin and azithromycin. This clinical trial results indicating potentially significant clinical benefits for patients with gonorrhea.

Table Of Content:

Part 01: Executive Summary
Part 02: Scope Of The Report
Part 03: Market Landscape

Part 04: Market Sizing

Part 05: Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape
Part 08: Geographic Landscape

Part 09: Decision Framework
Part 10: Drivers And Challenges

Get Detailed TOC @

Segmentation: Global Gonorrhea Treatment Market

Global Gonorrhea Treatment Market By Drug Class (Sulfonamides, Tetracycline, Aminopenicillins, Macrolides), Drugs (Erythromycin, Clarithromycin, Azithromycin, Roxithromycin and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Market Drivers

  • Rising prevalence of the gonorrhea worldwide is driving the growth of this market
  • Huge financial support to the researchers for developing novel intervention is boosting the market growth
  • High demand of disease specific novel treatment can also act as a market driver
  • Increase in incidence of unprotected sex has led to an increase in the prevalence gonorrhea can propel the growth of this market

Market Restraints

  • Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
  • Low healthcare budget in some developing countries is hamper the market growth

Inquire Regarding This Report

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing [email protected] . We are content with our glorious 99.9 % client satisfying rate.


Data Bridge Market Research 
US: +1 888 387 2818 
UK: +44 208 089 1725 
Hong Kong: +852 8192 7475
Email: [email protected]